You can buy or sell CKPT and other stocks, options, ETFs, and crypto commission-free!
Checkpoint Therapeutics, Inc. Common Stock, also called Checkpoint Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Read More Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Markets InsiderMar 15
Checkpoint Therapeutics Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results and recent corporate highlights for the full year ended December 31, 2018. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “During 2018, we continued to advan...
Simply Wall StMar 12
Do Insiders Own Shares In Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)?
The big shareholder groups in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented. Checkpoint Therapeutics is not a large...
-$0.30 per share
-$0.38 per share